LBLara Blömeke

Lara Blömeke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lara Blömeke has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Dieter Willbold

    Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum Jülich, Jülich, Germany

    6 shared publications
  • Oliver Bannach

    Institute of Biological Information Processing (Structural Biochemistry: IBI-7), Forschungszentrum Jülich, Jülich, Germany

    4 shared publications
  • Anneliese Cousin

    Institute of Biological Information Processing (Structural Biochemistry: IBI-7), Forschungszentrum Jülich, Jülich, Germany

    3 shared publications
  • Victoria Kraemer-Schulien

    Institute of Biological Information Processing (Structural Biochemistry: IBI-7), Forschungszentrum Jülich, Jülich, Germany

    3 shared publications
  • Andreas Kulawik

    Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich, Jülich, Germany

    2 shared publications
  • Anja Schaffrath

    Institute of Biological Information Processing (Structural Biochemistry: IBI-7), Forschungszentrum Jülich, Jülich, Germany

    2 shared publications

Latest Publications

  • Open Access

    Blood-based quantification of Aβ oligomers indicates impaired clearance from brain in ApoE ε4 positive subjects

    by Lara Blömeke, Fabian Rehn, Marlene Pils, Victoria Kraemer-Schulien, Anneliese Cousin, Janine Kutzsche, Tuyen Bujnicki, Silka D. Freiesleben, Luisa-Sophie Schneider, Lukas Preis, et al.

    Background: Quantification of Amyloid beta (Aβ) oligomers in plasma enables early diagnosis of Alzheimer’s Disease (AD) and improves our understanding of underlying pathologies. However, quantification necessitates an extremely sensitive and selective technology because of very low Aβ oligomer concentrations and possible interference from matrix components. Methods: In this report, we developed and validated a surface-based fluorescence distribution analysis (sFIDA) assay for quantification of Aβ oligomers in plasma. Results: The blood-based sFIDA assay delivers a sensitivity of 1.8 fM, an inter- and intra-assay variation below 20% for oligomer calibration standards and no interference with matrix components. Quantification of Aβ oligomers in 359 plasma samples from the DELCODE cohort reveals lower oligomer concentrations in subjective cognitive decline and AD patients than healthy Control participants. Conclusions: Correlation analysis between CSF and plasma oligomer concentrations indicates an impaired clearance of Aβ oligomers that is dependent on the ApoE ε4 status.


  • Open Access

    Tau protein aggregation associated with SARS-CoV-2 main protease

    by Raphael Josef Eberle, Mônika Aparecida Coronado, Ian Gering, Simon Sommerhage, Karolina Korostov, Anja Stefanski, Kai Stühler, Victoria Kraemer-Schulien, Lara Blömeke, Oliver Bannach, et al.

    The primary function of virus proteases is the proteolytic processing of the viral polyprotein. These enzymes can also cleave host cell proteins, which is important for viral pathogenicity, modulation of cellular processes, viral replication, the defeat of antiviral responses and modulation of the immune response. It is known that COVID-19 can influence multiple tissues or organs and that infection can damage the functionality of the brain in multiple ways. After COVID-19 infections, amyloid-β, neurogranin, tau and phosphorylated tau were detected extracellularly, implicating possible neurodegenerative processes. The present study describes the possible induction of tau aggregation by the SARS-CoV-2 3CL protease (3CLpro) possibly relevant in neuropathology. Further investigations demonstrated that tau was proteolytically cleaved by the viral protease 3CL and, consequently, generated aggregates. However, more evidence is needed to confirm that COVID-19 is able to trigger neurodegenerative diseases.


  • Open Access

    Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease

    by Janine Kutzsche, Sarah Schemmert, Tuyen Bujnicki, Christian Zafiu, Steffen Halbgebauer, Victoria Kraemer-Schulien, Marlene Pils, Lara Blömeke, Julia Post, Andreas Kulawik, et al.


  • Open Access

    Tau protein aggregation associated with SARS-CoV-2 main protease

    by Raphael Josef Eberle, Mônika Aparecida Coronado, Ian Gering, Karolina Korostov, Anja Stefanski, Kai Stühler, Victoria Kraemer-Schulien, Lara Blömeke, Oliver Bannach, Dieter Willbold

    The primary function of virus proteases is the proteolytic processing of the viral polyprotein. These enzymes can also cleave host cell proteins, which is important for viral pathogenicity, modulation of cellular processes, viral replication, the defeat of antiviral responses and modulation of the immune response. It is known that COVID-19 can influence multiple tissues or organs and that infection can damage the functionality of the brain in multiple ways. After COVID-19 infections, amyloid-β, neurogranin, tau and phosphorylated tau were detected extracellularly, implicating possible neurodegenerative processes. The present study describes the possible induction of protein aggregation by the SARS-CoV-2 3CL protease (3CL pro ) possibly relevant in neuropathology, such as aggregation of tau, alpha-synuclein and TPD-43. Further investigations demonstrated that tau was proteolytically cleaved by the viral protease 3CL and, consequently, generated aggregates. However, more evidence is needed to confirm that COVID-19 is able to trigger neurodegenerative diseases.


  • Open Access

    Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool

    by Anja Schaffrath, Sophia Schleyken, Aline Seger, Hannah Jergas, Pelin Özdüzenciler, Marlene Pils, Lara Blömeke, Anneliese Cousin, Johannes Willbold, Tuyen Bujnicki, et al.

    Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson’s disease (PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of diagnostic assays. Quantification of α-synuclein aggregates in body fluids is challenging, and requires highly sensitive and specific assays. Recent studies suggest that α-synuclein aggregates may be shed into stool. We used surface-based fluorescence intensity distribution analysis (sFIDA) to detect and quantify single particles of α-synuclein aggregates in stool of 94 PD patients, 72 isolated rapid eye movement sleep behavior disorder (iRBD) patients, and 51 healthy controls. We measured significantly elevated concentrations of α-synuclein aggregates in stool of iRBD patients versus those of controls (p = 0.024) or PD patients (p < 0.001). Our results show that α-synuclein aggregates are excreted in stool and can be measured using the sFIDA assay, which could support the diagnosis of prodromal synucleinopathies.


  • Open Access

    Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting

    by Lara Blömeke, Marlene Pils, Victoria Kraemer-Schulien, Alexandra Dybala, Anja Schaffrath, Andreas Kulawik, Fabian Rehn, Anneliese Cousin, Volker Nischwitz, Johannes Willbold, et al.

    The pathological hallmark of neurodegenerative diseases is the formation of toxic oligomers by proteins such as alpha-synuclein (aSyn) or microtubule-associated protein tau (Tau). Consequently, such oligomers are promising biomarker candidates for diagnostics as well as drug development. However, measuring oligomers and other aggregates in human biofluids is still challenging as extreme sensitivity and specificity are required. We previously developed surface-based fluorescence intensity distribution analysis (sFIDA) featuring single-particle sensitivity and absolute specificity for aggregates. In this work, we measured aSyn and Tau aggregate concentrations of 237 cerebrospinal fluid (CSF) samples from five cohorts: Parkinson’s disease (PD), dementia with Lewy bodies (DLB), Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), and a neurologically-normal control group. aSyn aggregate concentration discriminates PD and DLB patients from normal controls (sensitivity 73%, specificity 65%, area under the receiver operating curve (AUC) 0.68). Tau aggregates were significantly elevated in PSP patients compared to all other groups (sensitivity 87%, specificity 70%, AUC 0.76). Further, we found a tight correlation between aSyn and Tau aggregate titers among all patient cohorts (Pearson coefficient of correlation r = 0.81). Our results demonstrate that aSyn and Tau aggregate concentrations measured by sFIDA differentiate neurodegenerative disease diagnostic groups. Moreover, sFIDA-based Tau aggregate measurements might be particularly useful in distinguishing PSP from other parkinsonisms. Finally, our findings suggest that sFIDA can improve pre-clinical and clinical studies by identifying those individuals that will most likely respond to compounds designed to eliminate specific oligomers or to prevent their formation.